Results 41 to 50 of about 809,322 (319)

Short-term effect of growth hormone treatment in childhood leukemia survivors with growth hormone deficiency [PDF]

, 2022
Chungwoo Shin, Min Jeong Jang, Seongkoo Kim, Jae Wook Lee, Nack‐Gyun Chung, Bin Cho, Min Ho Jung, Byung‐Kyu Suh, Moon Bae Ahn   +8 more
openalex   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source

P371: HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

HemaSphere, 2022
N. Short, H. Kantarjian, F. Ravandi, M. Yilmaz, T. Kadia, P. Thompson, X. Huang, M. Konopleva, A. Ferrajoli, N. Jain, K. Sasaki, Y. Alvarado, G. Borthakur, C. Dinardo, M. Ohanian, W. Macaron, S. Kornblau, M. Zhao, M. Kwari, C. Loiselle, R. Delumpa, A. Milton, J. Rivera, S. Lewis, R. Garris, E. Jabbour   +25 more
doaj   +1 more source

PYCR1 inhibition in bone marrow stromal cells enhances bortezomib sensitivity in multiple myeloma cells by altering their metabolism

Molecular Oncology, EarlyView.
This study investigated how PYCR1 inhibition in bone marrow stromal cells (BMSCs) indirectly affects multiple myeloma (MM) cell metabolism and viability. Culturing MM cells in conditioned medium from PYCR1‐silenced BMSCs impaired oxidative phosphorylation and increased sensitivity to bortezomib.
Inge Oudaert, Lauren van den Broecke, Osman Aksoy, Judith Lind, Sonia Vallet, Arne Van der Vreken, Gamze Ates, Ann Massie, Ken Maes, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Klaus Podar, Eline Menu   +13 more
wiley   +1 more source

S149: LONG TERM OUTCOMES OF IFCG REGIMEN FOR FIRSTLINE TREATMENT OF PATIENTS WITH CLL WITH MUTATED IGHV AND WITHOUT DEL(17P)/TP53 MUTATION

HemaSphere, 2022
N. Jain, P. Thompson, J. Burger, A. Ferrajoli, K. Takahashi, Z. Estrov, G. Borthakur, P. Bose, T. Kadia, N. Pemmaraju, K. Sasaki, M. Konopleva, E. Jabbour, N. Garg, X. Wang, R. Kanagal-Shamanna, K. Patel, W. Wang, S. Wang, J. Jorgensen, W. Lopez, A. Ayala, W. Plunkett, V. Gandhi, H. Kantarjian, S. O’Brien, M. Keating, W. Wierda   +27 more
doaj   +1 more source

Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes

Haematologica, 2017
The only cytogenetic aberration defining a myelodysplastic syndrome subtype is the deletion of the long arm of chromosome 5, which, along with morphological features, leads to the diagnosis of myelodysplastic syndrome with isolated deletion of the long ...
Manja Meggendorfer, Claudia Haferlach, Wolfgang Kern, Torsten Haferlach   +3 more
doaj   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

P770: A COMPARATIVE STUDY OF LEUKEMIC TRANSFORMATION IN THERAPY-RELATED AND DE NOVO MYELODYSPLASTIC SYNDROME AFTER HYPOMETHYLATING AGENT FAILURE

HemaSphere, 2022
K. Kim, F. Ong, Z. Li, R. Kanagal-Shamanna, G. Montalban-Bravo, T. Kadia, E. Jabbour, N. Pemmaraju, D. Hammond, N. Short, F. Ravandi, Y. Alvarado, S. Pierce, X. Q. Dong, H. Kantarjian, G. Garcia-Manero, K. Chien   +16 more
doaj   +1 more source

Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up [PDF]

, 2020
Jérôme Paillassa, Édouard Cornet, Stéphanie Noël, Cécile Tomowiak, Stéphane Leprêtre, Sandrine Vaudaux, Jehan Dupuis, Alain Devidas, Bertrand Joly, Charlotte Petitdidier-Lionnet, Stéphanie Haïat, Clara Mariette, Catherine Thiéblemont, Didier Decaudin, Patricia Validire-Charpy, Bernard Drénou, Jean‐Claude Eisenmann, Mario Ojeda‐Uribe, Agnès Olivrie, Mohamed Touati, Olivier Lambotte, Olivier Hermine, Jean‐Michel Karsenti, Pierre Feugier, Willy Vaillant, Jean Gutnecht, Éric Lippert, Fabienne Huysman, Kamel Ghomari, Marouane Boubaya, Vincent Lévy, Jérémie Riou, Gandhi Damaj, Aline Schmidt, Mathilde Hunault, Xavier Troussard   +35 more
openalex   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source